Heparin - Analogs & derivatives
Research News and Information

Sunday, November 22, 2009

Growth inhibition of bovine pulmonary artery smooth muscle cells following long-term heparin treatment.

29 Nov 2009 Heparin (HP) inhibits pulmonary artery smooth muscle cell (PASMC) growth in vitro and vascular remodeling in vivo. Bârzu et al. (1994) suggested that the antiproliferative effect of HP on rat aortic smooth muscle cell in vitro diminishes with ... Read more...

Insights into the capillary electrophoresis separation of heparin disaccharides from nuclear magnetic resonance, pKa, and electrophoretic mobility measurements.

30 Aug 2009 Determination of the pK(a) values of heparin disaccharide functional groups can provide insights into the nature of glycosaminoglycan (GAG)-protein interactions and prove useful for optimization of the charged-based separations typically used in GAG ... Read more...

Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection.

30 Jul 2009 Itching erythematous or eczematous plaques around injection sites are quite frequent side effects of heparin treatment and clinical symptoms of delayed-type non-IgE-mediated allergic hypersensitivity (DTH) to heparin. For diagnosis, intradermal, ... Read more...

Latest indexed articles for 'Heparin - Analogs & derivatives'

These are the very latest articles for this heading:

• Growth inhibition of bovine pulmonary artery smooth muscle cells following long-term heparin treatment. 29 Nov 2009
• Insights into the capillary electrophoresis separation of heparin disaccharides from nuclear magnetic resonance, pKa, and electrophoretic mobility measurements. 30 Aug 2009
• Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection. 30 Jul 2009
• Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. 22 Jul 2009
• Practical prescribing of intravenous unfractionated heparin. 29 Jun 2009
• Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor. 13 Jun 2009
• Human C21orf63 is a heparin-binding protein. 24 May 2009
• Chemically modified heparin inhibits in vitro L-selectin-mediated human ovarian carcinoma cell adhesion. 29 Apr 2009
• Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. 25 Apr 2009
• Therapeutically targeting protein-glycan interactions. 7 Apr 2009
• Exploiting a (13)C-labelled heparin analogue for in situ solid-state NMR investigations of peptide-glycan interactions within amyloid fibrils. 29 Mar 2009
• APRIL is overexpressed in cancer: link with tumor progression. 14 Mar 2009
• Unfractionated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats. 28 Feb 2009
• AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study. 22 Jan 2009
• Characterization of the enhancing effect of protamine on the proliferative activity of hepatocyte growth factor in rat hepatocytes. 4 Jan 2009
• Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. 30 Dec 2008
• Differentiation of 3-O-sulfated heparin disaccharide isomers: identification of structural aspects of the heparin CCL2 binding motif. 7 Dec 2008
• Estrogen plays a critical role in AAV2-mediated gene transfer in ovarian cancer. 29 Nov 2008
• Heparin-paclitaxel conjugates using mixed anhydride as intermediate: synthesis, influence of polymer structure on drug release, anticoagulant activity and in vitro efficiency. 16 Nov 2008
• A model ternary heparin conjugate by direct covalent bond strategy applied to drug delivery system. 3 Nov 2008

See a longer list of these articles.

Technical information about 'Heparin'

Definition: A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.

Registry Number: 9005-49-6

Descriptor UI: D006493

Alternative terms: Heparin; Heparinic Acid; Liquaemin; Sodium Heparin; Heparin, Sodium; Heparin Sodium; alpha-Heparin; alpha Heparin;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; ultrastructure;

Pharmacological Action: Fibrinolytic Agents; Anticoagulants;

Tree Number: D09.698.373.400;

History Note: /therapeutic use was HEPARIN, THERAPEUTIC 1965